16 Jan GeneScape
Karen Malone, Ph.D., CEO
April 29 | 9:15am | Salone dei Cavalieri, Section 1
Leiden, Netherlands
(Private)
Genetically defined diseases, including rare disease populations are challenging to quantify, leading to prevalence underestimations. This weakens business cases, leads to unreliable forecasts, causes promising projects to be halted prematurely, and misaligns commercial strategies. Additionally, misdiagnosis further drives inefficient trial design, slow patient recruitment, and increases development costs. GeneScape provides prevalence estimates based on population genetics modelling, as well as literature based meta-analysis. We offer diagnosis-independent patient estimates with high genetic and geographic resolution, delivering more robust incidence and prevalence data than classical epidemiology by integrating 1.2 million genomes globally. This is further supported by our proprietary atlases in key therapeutic areas. Innovative companies that partner with GeneScape, enable stronger decision-making, optimized trial design, and more effective strategic planning through robust, genetics-driven target patient population insights.
